Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.5. rezultāts no 100.
9. lappuse
... obtain a toxic or harmful amount of the sub- stance contained therein within a rea- sonable time and not difficult for nor- mal adults to use properly , but does not mean packaging which all such children cannot open or obtain a toxic ...
... obtain a toxic or harmful amount of the sub- stance contained therein within a rea- sonable time and not difficult for nor- mal adults to use properly , but does not mean packaging which all such children cannot open or obtain a toxic ...
42. lappuse
... obtain evidence that any drug prod- uct labeled , represented , or promoted as an OTC daytime sedative ( or any similar or related indication ) is safe and effective for the purpose intended must comply with the requirements and ...
... obtain evidence that any drug prod- uct labeled , represented , or promoted as an OTC daytime sedative ( or any similar or related indication ) is safe and effective for the purpose intended must comply with the requirements and ...
47. lappuse
... obtain evidence that any drug prod- uct labeled , represented , or promoted for OTC use as an oral wound healing agent is safe and effective for the pur- pose intended must comply with the re- quirements and procedures governing the use ...
... obtain evidence that any drug prod- uct labeled , represented , or promoted for OTC use as an oral wound healing agent is safe and effective for the pur- pose intended must comply with the re- quirements and procedures governing the use ...
48. lappuse
... obtain evidence that any drug prod- uct labeled , represented , or promoted for OTC use for ingrown toenail relief is safe and effective for the purpose in- tended must comply with the require- ments and procedures governing the use of ...
... obtain evidence that any drug prod- uct labeled , represented , or promoted for OTC use for ingrown toenail relief is safe and effective for the purpose in- tended must comply with the require- ments and procedures governing the use of ...
49. lappuse
... obtain evidence that any drug prod- uct labeled , represented , or promoted for OTC use in the treatment of hypo- phosphatemia is safe and effective for the purpose intended must comply with the requirements and procedures gov- erning ...
... obtain evidence that any drug prod- uct labeled , represented , or promoted for OTC use in the treatment of hypo- phosphatemia is safe and effective for the purpose intended must comply with the requirements and procedures gov- erning ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning